A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Goldman J. W. , Mazieres J., Barlesi F., Dragnev K. H. , Koczywas M., Goskel T., ...Daha Fazla

FRONTIERS IN ONCOLOGY, cilt.10, 2020 (SCI İndekslerine Giren Dergi) identifier identifier